NIKKEI 225
38,303.39 -531.71 (-1.37%) HANG SENG
18,438.00 -41.37 (-0.22%) CRUDE OIL
78.18 -0.20 (-0.26%) GOLD FUTURES
2,325.10 +0.90 (+0.04%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,397.99 -205.26 (-0.41%)
Swedish Orphan Biovitrum AB (B6E.HA)
| Previous close | 23.92 |
| Open | 24.10 |
| Bid | 23.92 x N/A |
| Ask | 24.24 x N/A |
| Day's range | 24.10 - 24.10 |
| 52-week range | 16.32 - 25.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
- PR Newswire
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
